Discovery of a novel integron-borne aminoglycoside resistance gene present in clinical pathogens by screening environmental bacterial communities

42Citations
Citations of this article
140Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: New antibiotic resistance determinants are generally discovered too late, long after they have irreversibly emerged in pathogens and spread widely. Early discovery of resistance genes, before or soon after their transfer to pathogens could allow more effective measures to monitor and reduce spread, and facilitate genetics-based diagnostics. Results: We modified a functional metagenomics approach followed by in silico filtering of known resistance genes to discover novel, mobilised resistance genes in class 1 integrons in wastewater-impacted environments. We identified an integron-borne gene cassette encoding a protein that conveys high-level resistance against aminoglycosides with a garosamine moiety when expressed in E. coli. The gene is named gar (garosamine-specific aminoglycoside resistance) after its specificity. It contains none of the functional domains of known aminoglycoside modifying enzymes, but bears characteristics of a kinase. By searching public databases, we found that the gene occurs in three sequenced, multi-resistant clinical isolates (two Pseudomonas aeruginosa and one Luteimonas sp.) from Italy and China, respectively, as well as in two food-borne Salmonella enterica isolates from the USA. In all cases, gar has escaped discovery until now. Conclusion: To the best of our knowledge, this is the first time a novel resistance gene, present in clinical isolates, has been discovered by exploring the environmental microbiome. The gar gene has spread horizontally to different species on at least three continents, further limiting treatment options for bacterial infections. Its specificity to garosamine-containing aminoglycosides may reduce the usefulness of the newest semisynthetic aminoglycoside plazomicin, which is designed to avoid common aminoglycoside resistance mechanisms. Since the gene appears to be not yet common in the clinics, the data presented here enables early surveillance and maybe even mitigation of its spread.

References Powered by Scopus

Gapped BLAST and PSI-BLAST: A new generation of protein database search programs

63196Citations
N/AReaders
Get full text

Fast gapped-read alignment with Bowtie 2

36319Citations
N/AReaders
Get full text

MAFFT multiple sequence alignment software version 7: Improvements in performance and usability

31069Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Antibiotic resistance in the environment

1423Citations
N/AReaders
Get full text

Antibiotic resistome from the One-Health perspective: understanding and controlling antimicrobial resistance transmission

173Citations
N/AReaders
Get full text

The association between insertion sequences and antibiotic resistance genes

79Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Böhm, M. E., Razavi, M., Marathe, N. P., Flach, C. F., & Larsson, D. G. J. (2020). Discovery of a novel integron-borne aminoglycoside resistance gene present in clinical pathogens by screening environmental bacterial communities. Microbiome, 8(1). https://doi.org/10.1186/s40168-020-00814-z

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 51

59%

Researcher 25

29%

Professor / Associate Prof. 6

7%

Lecturer / Post doc 5

6%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 22

35%

Agricultural and Biological Sciences 18

29%

Immunology and Microbiology 16

25%

Medicine and Dentistry 7

11%

Article Metrics

Tooltip
Mentions
News Mentions: 5
Social Media
Shares, Likes & Comments: 66

Save time finding and organizing research with Mendeley

Sign up for free